As per the agreement, Eurofins STA will gain non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology.
The precise commercial terms of the agreement are covered by formal confidentiality provisions and cannot be disclosed, the companies said.
Eurofins STA was a counterparty to the third formal patent assertion suit filed by Genetic Technologies against ten companies in the US District Court for the District of Colorado.